E Fund Management Co. Ltd. Has $210,000 Stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

E Fund Management Co. Ltd. raised its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 10.0% in the fourth quarter, Holdings Channel reports. The fund owned 18,053 shares of the company’s stock after purchasing an additional 1,634 shares during the quarter. E Fund Management Co. Ltd.’s holdings in Intellia Therapeutics were worth $210,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in NTLA. State Street Corp increased its position in Intellia Therapeutics by 17.9% during the 3rd quarter. State Street Corp now owns 5,143,534 shares of the company’s stock worth $105,700,000 after purchasing an additional 780,754 shares in the last quarter. Hennion & Walsh Asset Management Inc. grew its stake in shares of Intellia Therapeutics by 125.2% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 120,997 shares of the company’s stock worth $1,411,000 after buying an additional 67,276 shares during the last quarter. Patient Square Capital LP acquired a new position in shares of Intellia Therapeutics during the third quarter worth $2,642,000. Charles Schwab Investment Management Inc. lifted its stake in shares of Intellia Therapeutics by 4.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 827,545 shares of the company’s stock valued at $17,006,000 after acquiring an additional 37,714 shares during the last quarter. Finally, Avanza Fonder AB acquired a new stake in shares of Intellia Therapeutics during the 4th quarter valued at $421,000. 88.77% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Intellia Therapeutics news, CEO John M. Leonard sold 26,807 shares of the company’s stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $12.18, for a total transaction of $326,509.26. Following the transaction, the chief executive officer now owns 941,115 shares in the company, valued at approximately $11,462,780.70. This represents a 2.77 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Over the last ninety days, insiders sold 29,000 shares of company stock worth $352,551. 3.20% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on NTLA shares. William Blair reaffirmed a “neutral” rating and issued a $14.00 target price on shares of Intellia Therapeutics in a report on Monday, November 18th. Morgan Stanley lowered shares of Intellia Therapeutics from an “overweight” rating to an “equal weight” rating and dropped their price objective for the company from $56.00 to $11.00 in a report on Monday, January 27th. Canaccord Genuity Group reiterated a “buy” rating and set a $90.00 target price on shares of Intellia Therapeutics in a research report on Tuesday, November 19th. Oppenheimer decreased their price target on shares of Intellia Therapeutics from $60.00 to $40.00 and set an “outperform” rating for the company in a research report on Monday, January 13th. Finally, Wedbush reaffirmed a “neutral” rating and set a $10.00 price target (down previously from $14.00) on shares of Intellia Therapeutics in a research note on Friday, January 10th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Intellia Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $37.56.

Intellia Therapeutics Stock Up 4.5 %

Shares of NTLA stock opened at $10.35 on Monday. Intellia Therapeutics, Inc. has a 52 week low of $8.30 and a 52 week high of $32.00. The firm has a 50 day moving average of $10.61 and a 200-day moving average of $15.07. The company has a market cap of $1.07 billion, a price-to-earnings ratio of -1.90 and a beta of 1.97.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.